Viking Therapeutics, Inc. (VKTX) vs Xenon Pharmaceuticals Inc. (XENE)

A side-by-side comparison of Viking Therapeutics, Inc. and Xenon Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — VKTX vs XENE

growth of $100 · dividends reinvested · last 10y
VKTX +2021.7% (+35.7%/yr)XENE +355.4% (+16.4%/yr)VKTX compounded faster over this window
02k4k6kStart $10020182020202220242026$2,122$455
VKTX XENE

VKTX vs XENE: by the numbers

  • •XENE is the larger company ($3.54B vs $3.31B market cap).
  • •Both run net losses; VKTX's is the smaller (0.00% vs -4612.13% net margin).

Metrics side by side

Valuation

MetricVKTXXENE
P/B ratio8.112.85

Profitability

MetricVKTXXENE
Gross margin0.00%66.09%
Operating margin0.00%-4974.27%
Net margin0.00%-4612.13%
ROE-130.98%-32.94%
ROIC-135.85%-35.27%

Growth (annualized)

MetricVKTXXENE
Total return CAGR (5Y)37.36%4.61%

Frequently asked

How have VKTX and XENE total returns compared?
Over the past 10 years, VKTX delivered 35.25% and XENE delivered 17.07% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.